Treatment Innovations

Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

• Treatment Innovations

Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

Nana Muazin July 9, 2026

By Jacob Bell Published July 9, 2026 In a significant blow to its strategic pivot toward neurodegenerative...

Read More Read more about Clinical Setbacks Terminate GSK-Alector Neuroscience Partnership

Biotech Industry Roundup: Legal Victories, Regulatory Pivots, and Clinical Milestones

• Treatment Innovations

Biotech Industry Roundup: Legal Victories, Regulatory Pivots, and Clinical Milestones

Raul Delapena Setiawan July 9, 2026

Published: July 8, 2026 The biotechnology sector continues to navigate a complex landscape of intellectual property disputes,...

Read More Read more about Biotech Industry Roundup: Legal Victories, Regulatory Pivots, and Clinical Milestones

From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape

• Treatment Innovations

From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape

Azzam Bilal Chamdy July 8, 2026

The pharmaceutical landscape has been fundamentally reshaped by the rapid ascent of glucagon-like peptide-1 (GLP-1) receptor agonists....

Read More Read more about From Diabetes to MASH: How the GLP-1 Revolution is Redefining the Biobanking Landscape

Navigating the Oral Frontier: Kailera’s HRS-7535 and the Complex Trade-off in Obesity Therapeutics

• Treatment Innovations

Navigating the Oral Frontier: Kailera’s HRS-7535 and the Complex Trade-off in Obesity Therapeutics

Basiran July 8, 2026

By Jonathan Gardner Published July 7, 2026 The global obesity epidemic has catalyzed a high-stakes race within...

Read More Read more about Navigating the Oral Frontier: Kailera’s HRS-7535 and the Complex Trade-off in Obesity Therapeutics

Moderna’s Second Act: Decoding the Future of mRNA, AI, and In Vivo Therapeutics

• Treatment Innovations

Moderna’s Second Act: Decoding the Future of mRNA, AI, and In Vivo Therapeutics

Nila Kartika Wati July 7, 2026

At its highly anticipated annual Science Day, held on June 25, Moderna signaled a profound evolution in...

Read More Read more about Moderna’s Second Act: Decoding the Future of mRNA, AI, and In Vivo Therapeutics

Insuring the Trip: Navigating the Liability Landscape of FDA-Approved Psilocybin

• Treatment Innovations

Insuring the Trip: Navigating the Liability Landscape of FDA-Approved Psilocybin

Muslim July 7, 2026

More than five decades after the Controlled Substances Act of 1970 relegated psilocybin to Schedule I—placing it...

Read More Read more about Insuring the Trip: Navigating the Liability Landscape of FDA-Approved Psilocybin

The Price of Parity: How Most-Favored-Nation Pricing is Rewiring Generic Drug Economics

• Treatment Innovations

The Price of Parity: How Most-Favored-Nation Pricing is Rewiring Generic Drug Economics

Basiran July 7, 2026

The landscape of American pharmaceutical pricing is undergoing a structural transformation. As the U.S. healthcare system grapples...

Read More Read more about The Price of Parity: How Most-Favored-Nation Pricing is Rewiring Generic Drug Economics

Breakthrough in Pain Management: Nexsphere-F Offers New Hope for Knee Osteoarthritis Patients

• Treatment Innovations

Breakthrough in Pain Management: Nexsphere-F Offers New Hope for Knee Osteoarthritis Patients

Lina Hope July 7, 2026

As the global burden of chronic musculoskeletal conditions continues to rise, the medical community is closely watching...

Read More Read more about Breakthrough in Pain Management: Nexsphere-F Offers New Hope for Knee Osteoarthritis Patients

The Dual Engine of Biotech: Oncology and Immunology Dominate 2026 Investment Landscape

• Treatment Innovations

The Dual Engine of Biotech: Oncology and Immunology Dominate 2026 Investment Landscape

Basiran July 7, 2026

By Gwendolyn Wu Published July 6, 2026 The biotechnology sector, a barometer for scientific innovation and capital...

Read More Read more about The Dual Engine of Biotech: Oncology and Immunology Dominate 2026 Investment Landscape

Beyond the PD-1 Era: The High-Stakes Evolution of Oncology at ASCO 2026

• Treatment Innovations

Beyond the PD-1 Era: The High-Stakes Evolution of Oncology at ASCO 2026

Suro Senen July 6, 2026

The global biotechnology sector is currently navigating a period of profound structural transformation. As the industry gathers...

Read More Read more about Beyond the PD-1 Era: The High-Stakes Evolution of Oncology at ASCO 2026